On September 20, 2022, AIM ImmunoTech Inc. announced that it has filed its definitive proxy statement in connection with the Company's upcoming 2022 annual meeting of stockholders, to be held on November 3, 2022, and has mailed this statement, along with a letter, to shareholders. The Company highlighted that the progress made in recent years and especially over past 18 months in repurposing lead drug Ampligen in oncology to benefit patients and all shareholders. In addition, the Company called on shareholders to support continued positive momentum by re-electing the aim board and discarding any materials received from Jorgl activist group.